Key result
Captopril ameliorated UUO-induced pro-fibrotic changes, an effect that was eliminated by co-administration with the prolyl oligopeptidase inhibitor S17092.
The anti-fibrotic properties of captopril in a mouse model of kidney injury are primarily mediated by Ac-SDKP via p44/42 MAPK and TGF-β1 signalling pathways.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for Ac-SDKP mediation of captopril anti-fibrosis; leaves open translation to human CKD.
AIM: Angiotensin-converting enzyme inhibitors (ACEi) are widely used to deter the progression of chronic kidney disease (CKD). Besides controlling hypertension and reduction of intra-glomerular pressure, ACEi appear to have anti-fibrotic effects in the renal cortex. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), an endogenous tetrapeptide that is degraded by ACE, has also been shown to ameliorate the pro-fibrotic phenotype displayed in CKD in our recent study. Whether the anti-fibrotic properties of ACEi are mediated by Ac-SDKP has not been fully investigated. METHODS: To delineate the role of Ac-SDKP in ACE blockade, 12-week-old male BALB/c mice underwent sham operation or unilateral ureteric obstruction (UUO). UUO mice were subjected to: (i) vehicle; (ii) captopril or (iii) captopril in conjunction with S17092, a prolyl oligopeptidase inhibitor. After 7 days, mice were sacrificed and kidneys harvested for analyses. RESULTS: After UUO, there were heightened expressions of collagen I, collagen III, fibronectin and α-SMA associated with significant levels of tubulointerstitial injury on histological examination. Furthermore, p44/42 mitogen-activated protein kinase (MAPK) and transforming growth factor beta 1(TGF-β1) signalling were upregulated. These were significantly ameliorated by captopril treatment alone but unaffected by co-administration of captopril with S17092. Captopril treatment had resulted in elevated urinary Ac-SDKP levels, an effect that was eliminated by the co-administration with S17092. CONCLUSION: This study allowed the investigation of the renoprotective property of ACEi in the absence of Ac-SDKP and proved conclusively that Ac-SDKP is the prime anti-fibrotic mediator of captopril, acting via p44/42 MAPK and TGF-β1 signalling pathways. Future research to expand CKD armamentarium should explore the utility of augmenting Ac-SDKP levels.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2017) studied Unilateral ureteric obstruction (CKD model). Captopril vs. Vehicle or captopril + S17092 was evaluated on Expressions of collagen I, collagen III, fibronectin and α-SMA, and tubulointerstitial injury. Captopril ameliorated UUO-induced pro-fibrotic changes, an effect that was eliminated by co-administration with the prolyl oligopeptidase inhibitor S17092.
Synapse has enriched 10 related papers. Consider them for comparative context: